Health
FDA authorizes fingerstick COVID-19 antibody test – Mass Device
Nirmidas Biotech announced this week that it received FDA emergency use authorization (EUA) for its COVID-19 test in point-of-care settings.
Nirmidas Biotech announced this week that it received FDA emergency use authorization (EUA) for its COVID-19 test in point-of-care settings.
Palo Alto, Calif-based Nirmidas Biotech’s MidaSpot rapid COVID-19 antibody combo detection kit uses fingerstick serology testing to detect IgG/IgM antibodies related to the SARS-CoV-2 virus causing COVID-19, according to a news release.
MidaSpot, touted by Nirmidas as the first point-of-care fingerstick COVID-19 test to receive EUA, can now be administered…
-
General22 hours agoDairy farmers devastated by floods across parts of New South Wales
-
Noosa News19 hours agoBrisbane’s Triffid forces redesign of $1.5 billion tower project
-
Noosa News22 hours agoMan dies in Gold Coast after rolling trailer pins him to lamp-post
-
General19 hours agoSussan Ley’s office says Bridget McKenzie made false claims about cabinet solidarity